The aqueous tuber extract of Pueraria tuberosa (Willd.) D.C. caused cytotoxic effect on HT 29 cell lines with down regulation of nuclear factor-kappa B (NF-κB)

Adeolu Alex Adedapo; Olusegun A Fagbohun; Christianah Dawurung; Ademola Adetokunbo Oyagbemi; Temidayo Olutayo Omobowale; Momoh Audu Yakubu

doi:10.1515/jcim-2016-0119

Article

The aqueous tuber extract of Pueraria tuberosa (Willd.) D.C. caused cytotoxic effect on HT 29 cell lines with down regulation of nuclear factor-kappa B (NF-κB)

Adeolu Alex Adedapo , Olusegun A Fagbohun , Christianah Dawurung , Ademola Adetokunbo Oyagbemi , Temidayo Olutayo Omobowale and Momoh Audu Yakubu

Published/Copyright: October 18, 2017

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Complementary and Integrative Medicine Volume 16 Issue 4

Abstract

Background

Pueraria tuberosa (Willd) D.C. (Fabaceae) tubers are already used in traditional medicine by Ayurvedic physicians for the management of fertility disorders, general weakness, and also as anti-ageing therapies. Other known pharmacological properties include: anti-hyperglycemics, hepatoprotective, anti-hyperlipidemic, diuretic, nutritive, and anti-fertility agents in male rats.

Methods

The anti-proliferative effect of the aqueous tuberous root extract of Pueraria tuberosa on vascular smooth muscle cells (VSMCs) and Human Colorectal Adenocarcinoma Cell lines (HT-29) was investigated using the Cell Titer 96 MTT Proliferation Assay where the viable cells were seeded at a density of 5 × 10⁴ (100 µL/well). For VSMC, log concentrations of the extract at 200 and 800 µg/mL were added and incubated for 24 and 48 h time points. Incubation of the extract in the presence of vascular endothelial growth factor (VEGF) and ET-1 was also conducted at different times. Concentrations of the extract (200, 400 and 700 µg/mL) were also added and incubated with the HT 29 cell lines for 24, 48 and 72 h time points. The effect of the tuber aqueous extract of the plant on nuclear factor-κB (NF-κB) expression after 2 h was also carried out using immunoblotting technique.

Results

The result showed that after 24 h, the effect of the extract in the presence of the mitogens and on the VSMC was more of proliferation. However, at 48 h, the 200 µg/mL dose, both alone and in the presence of VEGF caused 11.1% and 25.9% decreases respectively, in cell proliferation. In the HT 29 cytotoxic study the 200 µg/mL concentration caused the greatest cytotoxic effect at 77.1% cell inhibition followed by 400 µg/mL concentration at 71.4% after 72 h. The immunoblotting assay showed a down regulation of NF-κB expressions with 0.7 µg/mL concentration showing the greatest effect. NF-κB, a pro-inflammatory agent is increasingly recognized as a crucial player in many steps of cancer initiation and progression.

Conclusions

It could therefore be concluded that the aqueous root extract of Pueraria tuberosa possesses cytotoxic effect and could serve as a lead compound for anticancer and anti-inflammatory agents.

Keywords: anticancer; HT 29; inflammation; NF-κB; Pueraria tuberosa; VSMC

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was supported with a grant (TETFUND/DESS/NRF/UI IBADAN/STI/VOL. 1/B2.20.11) received from the National Research Foundation of the Tertiary Education Trust Fund (TETFUND), Nigeria.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

[1] Mathers C, Boschi-Pinto C, Lopez A, Murray C. Cancer incidence, mortality and survival by site for 14 regions of the world. Lyon, France: World Health Organization; 2001.Search in Google Scholar

[2] Lage H, Duarte N, Coburger C, Hilgeroth A, Ferreira MJU. Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells. Phytomed. 2010;17:441–48.10.1016/j.phymed.2009.07.009Search in Google Scholar

[3] Carter S, Livingston R. Principle of cancer chemotherapy. In: Carter S, Glatstein E, Livingston R, editors. principles of cancer treatment. New York, NY: McGraw-Hill; 1982. p. 95–110.Search in Google Scholar

[4] Cragg M, Newman D. Natural product drugs discovery in next millennium. Frederick, MD: National Cancer Institute; 2001.10.1007/978-1-4615-1455-8_3Search in Google Scholar

[5] Stevigny C, Bailly C, Quetin-Leclercq J. Cytotoxic and antitumor potentialities of aporphinoid alkaloids. Curr Med Chem—Anti-Cancer Agents. 2005;5:173–82.10.2174/1568011053174864Search in Google Scholar

[6] Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Natural Prod. 2007;70:461–77.10.1021/np068054vSearch in Google Scholar

[7] Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Natural Prod. 2012;75:311–35.10.1021/np200906sSearch in Google Scholar

[8] Pandey GS, Chunekar KC, Vidari K, editors. Bhav Prakash Nighantu, vol. 1. Varanasi: Chaukambha Vidya Bhavan, 1998:388–89.Search in Google Scholar

[9] Tripathi YB, Nagwani S, Mishra P, Jha A, Rai SP. Protective effect of Pueraria tuberosa DC. embedded biscuit on cisplatin-induced nephrotoxicity in mice. J Nat Med. 2012;66:109–18.10.1007/s11418-011-0559-1Search in Google Scholar PubMed

[10] Handa SS, Kaul MK. Recent development of some natural products. In: Handa SS, Kaul MK, editors. Supplement to cultivation and utilization of medical plants. Jammu-Tawi: CSIR, RPL; 1996. p. 53–96.Search in Google Scholar

[11] Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J Nat Prod. 2003;66:788–92.10.1021/np0203887Search in Google Scholar PubMed

[12] Gupta RS, Sharma R, Sharma A. Antifertility effects of Pueraria tuberosa root extract in male rats. Pharm Biol. 2004;42:3–9.10.1080/13880200490902491Search in Google Scholar

[13] Tanwar YS, Goyal S, Ramawat KG. Hypolipidemic effects of tubers of Indian Kudzu (Pueraria tuberosa). J Herb Med Toxicol. 2008;2:21–25.Search in Google Scholar

[14] Joshi BS, Kamat VN. Tuberosin, a new pterocarpan from Pueraria tuberosa DC. J Chem Soc Perkin. 1993;9:907–11.10.1039/p19730000907Search in Google Scholar

[15] Khan RA, Agarwal PK, Kapil RS. Puetuberosanol an epoxychalcanol from Pueraria tuberosa. Phytochem. 1996;42:42–44.10.1016/0031-9422(95)00845-4Search in Google Scholar

[16] Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis—effects of lipid lowering therapy. J Atheroscler Thromb. 2011;18:351–58.10.5551/jat.7591Search in Google Scholar PubMed

[17] Bagad AS, Joseph JA, Bhaskaran N, Agarwal A. Comparative evaluation of anti-inflammatory activity of Curcuminoids, Turmerones, and aqueous extract of Curcuma longa. Adv Pharmacol Sc. 2013;Article ID 805756:7 pages.10.1155/2013/805756Search in Google Scholar

[18] Pandey N, Chaurasia JK, Tiwari OP, Tripathi YB. Antioxidant properties of different fractions of tubers from Pueraria tuberosa Linn. Food Chem. 2007;105:19–22.10.1016/j.foodchem.2007.03.072Search in Google Scholar

[19] Van De Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Lansenhuijsen MM. A tetrazolium-based colometric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994;174:311–20.10.1016/0022-1759(94)90034-5Search in Google Scholar

[20] Chiong M, Cartes-Saavedra B, Norambuena-Soto I, Mondaca-Ruff D, Morales PE, Garcia-Miquel M, et al. Mitochondrial metabolism and the control of vascular smooth muscle cell proliferation. Front Cell Dev Biol. 2014;2:72 pages.10.3389/fcell.2014.00072Search in Google Scholar PubMed PubMed Central

[21] Ho-Tin-Noe B, Le Dall J, Gomez D, Louedec L, Vranclex R, El-Bouchtaoui M, et al. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ Res. 2011;109:1003–14.10.1161/CIRCRESAHA.110.235390Search in Google Scholar PubMed

[22] Ragolia L, Palaia T, Paric E, Maesaka JK. Prostaglandin D2 synthase inhibits the exaggerated growth phenotype of spontaneously hypertensive rat vascular smooth muscle cells. J Biol Chem. 2003;278:22175–81.10.1074/jbc.M302769200Search in Google Scholar PubMed

[23] Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 2007;39:86–93.Search in Google Scholar PubMed

[24] Freise C, Querfeld U. The lignan (+)-episesamin interferes with TNF-α-induced activation of VSMC via diminished activation of NF-κB, ERK1/2 and AKT and decreased activity of gelatinases. Acta Physiol (Oxf). 2015;213:642–52.10.1111/apha.12400Search in Google Scholar PubMed

[25] Lusis AJ. Atherosclerosis. Nature. 2000;407:233–41.10.1038/35025203Search in Google Scholar PubMed PubMed Central

[26] Roberts E, Cossigny DAF, Quan GMY. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer Vol. 2013;Article ID 418340: 8 pages. Hindawi Publications.10.1155/2013/418340Search in Google Scholar PubMed PubMed Central

[27] Li Q, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.10.1038/nri910Search in Google Scholar PubMed

[28] Staudt LM, Karin M. The nuclear factor NF-kB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.10.1101/cshperspect.a001651Search in Google Scholar PubMed PubMed Central

[29] Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135–42.10.1172/JCI11914Search in Google Scholar PubMed PubMed Central

[30] Karin M, Cao Y, Greten FR, Li ZW. NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.10.1038/nrc780Search in Google Scholar PubMed

Received: 2016-10-15

Accepted: 2017-07-11

Published Online: 2017-10-18

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jcim-2016-0119

Keywords for this article

anticancer; HT 29; inflammation; NF-κB; Pueraria tuberosa; VSMC